Legal status · United States
Is CT-868 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. CT-868 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile.
CT-868 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Never approved. Roche discontinued development in July 2026, prioritising enicepatide, the once-weekly dual agonist from the same Carmot acquisition. |
| FDA approval status | Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes. |
| Human studies cited | 1 of 2 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the CT-868 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
CT-868 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What CT-868 is
Its phase 2 in 103 adults with type 2 diabetes cut glycated haemoglobin 1.61 to 2.24 percentage points against placebo but produced only 2.9 percent weight loss. Roche discontinued it in July 2026 in favour of another compound from the same acquisition.
1 billion dollars. It later received the nonproprietary name acmopatide.
Mechanism: A dual agonist at the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, described by its developers as fully biased toward cyclic AMP signalling. Signalling bias means the ligand preferentially activates the G protein and cyclic AMP arm of receptor signalling while producing little beta-arrestin recruitment, which reduces receptor internalisation and desensitisation.
Regulatory history: Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for CT-868 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
CT-868 in other countries
Frequently asked questions
Is CT-868 legal in the United States?
No. CT-868 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 1 human study is cited on its profile. Note: Never approved. Roche discontinued development in July 2026, prioritising enicepatide, the once-weekly dual agonist from the same Carmot acquisition.
Can I buy CT-868 in the United States?
No approved product exists to buy. In the United States CT-868 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Never approved. Roche discontinued development in July 2026, prioritising enicepatide, the once-weekly dual agonist from the same Carmot acquisition.
Is CT-868 FDA approved?
No. FDA status: Not approved. Development was discontinued by Roche in July 2026 after the phase 2 trial in type 2 diabetes.. Current US classification: "Investigational, not approved". On the evidence, 1 human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for CT-868 live on its compound profile.
CT-868 profileThis page is general information about the regulatory status of CT-868 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.